Richard Hargreaves, Ph.D., FBPhS (Observer)
Senior Vice President, Head of Neuroscience TRC Research and Early Development, Bristol Myers Squibb
Richard Hargreaves is senior vice president, head of neuroscience research and early development at Bristol Myers Squibb. Prior to Bristol Myers Squibb, Dr. Hargreaves served as corporate vice president, head of neuroscience and imaging research at Celgene, vice president, head of the New Indications Research Unit (NIRU) and Research & Early Development Centers of Excellence (RED-CoEs) at Biogen, and as vice president discovery head for neuroscience and vice president imaging at Merck Research Laboratories. Dr. Hargreaves has led teams that have advanced numerous novel CNS PET imaging agents and neuroscience drug candidates to the clinic contributing to the successful registration of MAXALT® for migraine, EMEND® and EMEND-IV® for chemotherapy-induced nausea and vomiting, BELSOMRA ® for insomnia, Ajovy® for prevention of migraine, Ubrelvy® for acute migraine and Zeposia® for relapsing multiple sclerosis. He is a board member for Target ALS and on the scientific advisory board of the Silverstein Parkinson’s disease foundation. Dr. Hargreaves has published more than 200 journal articles and been recognized by awards from the American Society for Clinical Pharmacology and Therapeutics (ASPCT) for his work on CNS discovery imaging and the British Pharmacological Society with the Sir James Black Award for Drug Discovery. Dr. Hargreaves holds a BSc and Ph.D. from Chelsea/King’s College, London University UK and is an Honorary Fellow of the British Pharmacological Society (FBPhS).